GlassScriptPhysician profile
Dalia Aziz
NPI 1720540545
$1,377.31
in general payments reported to CMS, 2019-2025
14 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2021: $13.82 · 2022: $292 · 2023: $272 · 2024: $345 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.82 |
| Education | $139.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $527.12 | 2023-2025 | Farxiga, Wainua, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.76 | 2022-2025 | Jardiance |
| Amgen INC. | $140.20 | 2022-2025 | Repatha |
| Glaxosmithkline, LLC. | $109.57 | 2019 | |
| Medtronic, INC. | $70.92 | 2023-2024 | Symplicity G3, Corevalve Evolut R |
| Philips North America LLC | $59.31 | 2022 | |
| Lantheus Medical Imaging, INC. | $37.80 | 2022-2023 | Definity |
| Chiesi USA, INC. | $32.29 | 2023-2024 | Kengreal, Cleviprex |
| Bayer Healthcare Pharmaceuticals INC. | $30.24 | 2022 | |
| Pfizer INC. | $29.55 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.79 | 2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $20.89 | 2025 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $19.04 | 2025 | |
| Mylan Specialty L.P. | $18.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalia Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.